In re Asbestos Products Liability Litigation (NO. VI)

256 F.R.D. 151, 2009 U.S. Dist. LEXIS 14881, 2009 WL 466381
CourtDistrict Court, E.D. Pennsylvania
DecidedFebruary 25, 2009
DocketMDL Docket No. 875
StatusPublished
Cited by15 cases

This text of 256 F.R.D. 151 (In re Asbestos Products Liability Litigation (NO. VI)) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Asbestos Products Liability Litigation (NO. VI), 256 F.R.D. 151, 2009 U.S. Dist. LEXIS 14881, 2009 WL 466381 (E.D. Pa. 2009).

Opinion

[152]*152MEMORANDUM

EDUARDO C. ROBRENO, District Judge.

I. INTRODUCTION

In 2005 and early 2008, certain Defendants issued subpoenas to physicians seeking the production of certain documents from the physicians who had issued a number of diagnosing reports or opinions produced by [153]*153Plaintiffs in the course of litigation in MDL 875.1

Before the court are motions to quash these subpoenas, filed on behalf of Dr. Lax-minaraya C. Rao, Dr. Richard Bernstein, and Dr. Jay Segarra (together referred to as the “Doctors”), either through their own attorneys or through counsel for MDL 875 Plaintiffs. In response, certain Defendants have filed motions to compel production of documents in accordance with the subpoenas.

For the reasons that follow, the court finds that the objections to the subpoenas by the Doctors and the Plaintiffs lack merit and accordingly, the motions to quash will be denied. However, the court finds the subpoenas served upon the Doctors are too broad and overly burdensome, and the subpoenas will be enforced only as to the documents related to diagnoses of asbestos related conditions relied upon by Plaintiffs in MDL 875.

II. BACKGROUND

The Judicial Panel on Multidistrict Litigation has consolidated all of the federal asbestos products liability personal injury claims in the Eastern District of Pennsylvania for pretrial proceedings.2 Defendants in this matter are alleged to have caused or contributed to the cause of asbestos related personal injuries. Plaintiffs are those individuals seeking damages for these asbestos related injuries.

In the course of the MDL 875 litigations, Defendants issued subpoenas to the Doctors who diagnosed Plaintiffs as being afflicted with various diseases, mostly resulting from occupational asbestos exposure. The subpoenas seek, inter alia, production of the Doctors’ screening medical documents.3 4 The Doctors, argue that the subpoenas should be quashed because: (1) production of the documents requested by the subpoenas would violate the Health Insurance Portability and Accountability Act (“HIPAA”); (2) the subpoenas are exempt from discovery because the Doctors were acting as consulting experts under Federal Rule of Civil Procedure 26(b) (4)(B); (3) The subpoenas are overly broad and unduly burdensome; and (4) the notice of the subpoenas to opposing counsel was untimely, making the subpoenas procedurally deficient under Federal Rule of Civil Procedure 45(b)(1). Defendants, in turn, have filed motions to compel full compliance with the subpoenas.

For the purposes of this opinion, substantive objections raised by the Doctors will be addressed jointly. Addressed in a separate section will be Plaintiffs’ objection to the issuance of the subpoenas based on untimely notice.

III. JURISDICTION

Multidistrict litigation (“MDL”) is governed by 28 U.S.C. § 1407, which specifically grants district court judges in transferee courts the “powers of a district judge in any district for the purpose of conducting pretrial depositions in such coordinated or consolidated pretrial proceedings”. 28 U.S.C. § 1407(b). Some courts have read this grant of authority to conflict with the general guidance of Federal Rule of Civil Procedure 45 which, in pertinent part, states that “the [154]*154court by which a subpoena was issued shall quash or modify the subpoena. ...” Fed. R.Civ.P. 45(c)(3)(A). Several courts have reconciled the language of both the statute and the federal rule to find that the statute’s reference to “depositions” encompasses document production subpoenas as well. In re Clients & Former Clients of Baron & Budd, P.C., 478 F.3d 670, 671 (5th Cir.2007); see also In re Sunrise Sec. Litig., 130 F.R.D. 560, 586 (E.D.Pa.1989); In re Welding Rod Prod. Liab. Litig., 406 F.Supp.2d 1064, 1065 (N.D.Cal.2005); United States ex rel. Pogue v. Diabetes Treatment Ctrs. of America, Inc., 238 F.Supp.2d 270, 274-75 (D.D.C.2002); In re San Juan Dupont Plaza Hotel Fire Litig., 117 F.R.D. 30, 32-33 (D.P.R.1987).5

This accommodation seems reasonable in light of the purpose of the statute to coordinate and consolidate pretrial proceedings, providing centralized management “to ensure ‘just and efficient’ conduct”. United States ex rel. Pogue, 238 F.Supp.2d at 273 (quoting In re New York City Mun. Sec. Litig., 572 F.2d 49, 51 (2d Cir.1978)). To hold that a court presiding over an MDL case could not enforce a motion to compel would hamper the ability of an MDL court to coordinate and consolidate pretrial proceedings. United States ex rel. Pogue v. Diabetes Treatment Ctrs. of America, 444 F.3d 462, 468 (6th Cir.2006).

If that were the case, motions to compel oral depositions would be heard in one court, while motions seeking documents in the same case would be heard by another.6 The Eastern District of Pennsylvania is the district in which the MDL proceeding is pending. Accordingly, under § 1407, the court has jurisdiction to address motions to compel compliance with the subpoenas and motions to quash the subpoenas whether they request oral testimony or production of documents.

IV. DISCUSSION OF THE MERITS

A. Segarra and Rao are Not Covered Under HIPAA and Their Litigation Screening Documents are Not Privileged Material.

Doctors Segarra and Rao rely on two arguments. First, they contend that under HIPAA they are barred from producing the documents requested by the subpoena; and second, that the physician-patient privilege requires them to obtain the consent of each Plaintiff before releasing the information requested by the subpoena. The court disagrees.

As to the first argument, the medical evaluations provided by Doctors Segarra and Rao are not covered by HIPAA. HIPAA governs the release of protected health information — individually identified health information transmitted or maintained in any form. 45 C.F.R. § 160.103. Entities covered by HIPAA include: “(1) a health plan, (2) a health care clearinghouse, and (3) a health care provider ...” 45 C.F.R. § 160.102. A health care provider includes a provider of medical services such as physician services. 45 C.F.R. §

Related

Cite This Page — Counsel Stack

Bluebook (online)
256 F.R.D. 151, 2009 U.S. Dist. LEXIS 14881, 2009 WL 466381, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-asbestos-products-liability-litigation-no-vi-paed-2009.